- Research areas
- High tech medicine
High tech medicine
High-tech medical interventions are placed in an area of tension due to a short life-cycle, budget constraints and efficacy/ safety aspects. These AIHTA reports support decision-making based on the best available evidence.
Research projects
HTA Strategy for Lithuania
Project leaders: Claudia Wild
Project team: Claudia Wild, Tarquin Mittermayr
Duration: February 2015 - July 2015
Publication: HTA Decision Support Document No. 90a: https://eprints.aihta.at/1064/
Evaluation of individual medical procedures - MEL 2015
Project leaders: Claudia Wild
Project co-operation: LBI-HTA staff for individual reviews
Duration: November 2014 – April 2015
Publications
Positron emission tomography/ Computer tomography (PET/ CT): need-assessment for planning
Project leaders: Claudia Wild
Project team: Claudia Wild
Duration: September 2014 - December 2014
Publication: LBI-HTA Project report No. 77: https://eprints.aihta.at/1045
Opportunities and strategies to drive appropriate use of MRI in Austria
Project leaders: Claudia Wild
Project team: Julia Mayer-Ferbas
Duration: April 2014 – November 2014
Publication: HTA Projektbericht Nr. 80: https://eprints.aihta.at/1043/
Efficacy of Hyperthermia treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix carcinoma and Soft tissue sarcoma patients
Project leaders: Claudia Wild
Project team: Claudia Wild, Andreas Kirisits
Duration: June 2012 – December 2012
Publication: HTA - Projectreport Nr. 36/Update 2012: https://eprints.aihta.at/986/
- Editorial 2012
Concerning the final report "Hyperthermia: A systematic review" of Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010
Sauer, et al.
Strahlentherapie und Onkologie, 2012, Volume 188(3) 209-215.
- Antwort auf Editorial 2012
The final publication is available at link.springer.com
Link: http://link.springer.com/search?query=10.1007%2Fs00066-012-0265-2
Because of the low quality evidence, hyperthermia cannot be included in the benefit catalogue for oncologic indications. Strong commercial interests are presumed behind the editorial of R. Sauer et al.
C. Wild et al.
Strahlentherapie und Onkologie, 2013, Volume 189(1):81-6.
- Erratum
Erratum to: Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.
Strahlentherapie und Onkologie, 2013, Volume 189 (3) 271-272.
Evaluation of individual medical services - MEL 2013
Project leaders: Claudia Wild
Marisa Warmuth
Project co-operation: LBI-HTA staff for individual reviews
Duration: November 2012 - April 2013
Evaluation of individual medical procedures - MEL 2014
Project leaders: Claudia Wild
Project co-operation: LBI-HTA staff for individual reviews
Duration: November 2013 – April 2014
Publications
Evaluation of individual medical procedures - MEL 2013
Project leaders: Claudia Wild
Marisa Warmuth
Project co-operation: LBI-HTA staff for individual reviews
Duration: November 2012 - April 2013
Cervical cancer screening: p16/KI-67 Dual Stain test (CINtec® PLUS) in the triage of equivocal results or mild to moderate dysplasia in pap cytology
Project leaders: Ingrid Zechmeister-Koss
Duration: April 2013 - September 2013
Publicationen:
- HTA project report No. 72: https://eprints.aihta.at/1009/
- Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG 2014; DOI: 10.1111/1471-0528.13076
Cost- and Budget-Impact-Analysis of an Increase in Day Surgery for Selected Indications
Project leaders: Ingrid Zechmeister-Koss
Project team: Ingrid Zechmeister-Koss
Duration: April 2014 - May 2014
Publication: LBI-HTA Projektbericht Nr. 71: https://eprints.aihta.at/1035
